Improved oral p-selectin blocker for prophylactic sickle cell disease therapy
Ended Project Grant Awarded Last action
- Award ID
- R44HL123059
- Recipient
-
Vanguard Therapeutics, Inc. UEI W27EZJ6JUGH3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,992,124
Award facts
- Assistance listing
- 93.839 Blood Diseases and Resources Research
- Completion date
- Originally
- Place of performance
- Half Moon Bay, CA, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$200 | |
| Amendment | $0 | |
| Amendment | $324,169 | |
| Original award | $1,668,155 |
Quick answers
Who received award R44HL123059?
R44HL123059 was awarded to Vanguard Therapeutics, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 1, 2014.
How much is award R44HL123059 worth?
$1,992,124 has been obligated on R44HL123059.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award